The guideline was issued last week in a move to reform the management of clinical trials in the country.
WuXi cited the recent regulatory changes in its announcement of the acquisition, noting the opportunities presented by the reform.
According to the company, the acquisition is a strategic step forward to expand its clinical research capabilities in the US and globally.
The Austin, Texas-headquartered contract clinical research organization will operate as a wholly-owned subsidiary of WuXi. WuXi’s China-based Clinical Development Service (CDS) team will be integrated into the new business unit.
Dr. Ge Li WuXi AppTec chairman and CEO commented in a press release: "This business combination lays the groundwork for the creation of an integrated global clinical service organization with global expertise and global network."